HCPCS Level II code J3304 describes a preservative-free, extended-release, microsphere formulation of triamcinolone acetonide, 1 mg, administered as a therapeutic corticosteroid injection for localized inflammatory conditions. This code is nationally relevant because it captures claims for a specialized injectable corticosteroid formulation that can affect utilization, billing patterns, and payer coverage decisions for musculoskeletal and joint-related care. The code is used across outpatient settings where intra-articular or periarticular injections are performed.

Key payers in the scope of national coverage and benchmarking include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an explanation of the clinical and billing context for the product, the typical sites of service where the injection is administered, and the implications for claims coding and documentation. The publication outlines expected benchmarks and payer considerations, summarizes relevant policy and coverage themes, and provides clinical context about the therapeutic role of an extended-release triamcinolone formulation. Data not available in the input will be noted where applicable.